BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $42

Futu News00:31 · Ratings

Buy Rating Reiterated for 4D Molecular Therapeutics Amid Strategic Advancements and Undervalued Commercial Prospects

TipRanksJan 11 23:36 · Ratings

BMO Capital Downgrades 4D Molecular Therapeutics(FDMT.US) to Hold Rating, Cuts Target Price to $15

Futu NewsJan 11 07:32 · Ratings

Cautious Outlook for 4D Molecular Therapeutics Amid Limited Therapy Durability and Competitive Pressures

TipRanksJan 11 06:55

4D Molecular, FDA Agree on Phase 3 Design for DME Candidate

Seeking AlphaJan 11 00:18

4D Molecular Therapeutics to Focus Pipeline on Wet AMD, Cystic Fibrosis Drug Candidates

MT NewswiresJan 10 21:53